BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23937976)

  • 1. A rare missense variant abrogates the signaling activity of tetherin/BST-2 without affecting its effect on virus release.
    Sauter D; Hotter D; Engelhart S; Giehler F; Kieser A; Kubisch C; Kirchhoff F
    Retrovirology; 2013 Aug; 10():85. PubMed ID: 23937976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging role of the host restriction factor tetherin in viral immune sensing.
    Hotter D; Sauter D; Kirchhoff F
    J Mol Biol; 2013 Dec; 425(24):4956-64. PubMed ID: 24075872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLR-4 engagement of dendritic cells confers a BST-2/tetherin-mediated restriction of HIV-1 infection to CD4+ T cells across the virological synapse.
    Blanchet FP; Stalder R; Czubala M; Lehmann M; Rio L; Mangeat B; Piguet V
    Retrovirology; 2013 Jan; 10():6. PubMed ID: 23311681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates.
    Chen CY; Shingai M; Welbourn S; Martin MA; Borrego P; Taveira N; Strebel K
    J Virol; 2016 Dec; 90(24):11062-11074. PubMed ID: 27681141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation.
    Janvier K; Pelchen-Matthews A; Renaud JB; Caillet M; Marsh M; Berlioz-Torrent C
    PLoS Pathog; 2011 Feb; 7(2):e1001265. PubMed ID: 21304933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
    Kueck T; Neil SJ
    PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction.
    Le Tortorec A; Willey S; Neil SJ
    Viruses; 2011 May; 3(5):520-40. PubMed ID: 21994744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulation of NF-κB activity by the HIV restriction factor BST2.
    Tokarev A; Suarez M; Kwan W; Fitzpatrick K; Singh R; Guatelli J
    J Virol; 2013 Feb; 87(4):2046-57. PubMed ID: 23221546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.
    Lucas TM; Janaka SK; Stephens EB; Johnson MC
    PLoS One; 2012; 7(12):e51741. PubMed ID: 23284757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetherin/BST-2: Restriction Factor or Immunomodulator?
    Li SX; Barrett BS; Guo K; Santiago ML
    Curr HIV Res; 2016; 14(3):235-46. PubMed ID: 26957198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities.
    Cocka LJ; Bates P
    PLoS Pathog; 2012 Sep; 8(9):e1002931. PubMed ID: 23028328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
    Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
    J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single Amino Acid Substitution N659D in HIV-2 Envelope Glycoprotein (Env) Impairs Viral Release and Hampers BST-2 Antagonism.
    Dufrasne FE; Lombard C; Goubau P; Ruelle J
    Viruses; 2016 Oct; 8(10):. PubMed ID: 27754450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene.
    Nikovics K; Dazza MC; Ekwalanga M; Mammano F; Clavel F; Saragosti S
    PLoS One; 2012; 7(4):e35411. PubMed ID: 22530020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
    Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
    Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
    Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
    Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innate sensing of HIV-1 assembly by Tetherin induces NFκB-dependent proinflammatory responses.
    Galão RP; Le Tortorec A; Pickering S; Kueck T; Neil SJ
    Cell Host Microbe; 2012 Nov; 12(5):633-44. PubMed ID: 23159053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.
    Sauter D; Hué S; Petit SJ; Plantier JC; Towers GJ; Kirchhoff F; Gupta RK
    Retrovirology; 2011 Dec; 8():103. PubMed ID: 22171785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetherin restricts direct cell-to-cell infection of HIV-1.
    Kuhl BD; Sloan RD; Donahue DA; Bar-Magen T; Liang C; Wainberg MA
    Retrovirology; 2010 Dec; 7():115. PubMed ID: 21184674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue.
    Schindler M; Rajan D; Banning C; Wimmer P; Koppensteiner H; Iwanski A; Specht A; Sauter D; Dobner T; Kirchhoff F
    Retrovirology; 2010 Jan; 7():1. PubMed ID: 20078884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.